Sentynl Therapeutics, Inc., a wholly-owned subsidiary of Zydus Lifesciences Limited , has entered into an option and license agreement with Mereo BioPharma Group plc for alvelestat. The agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) in the United States, expanding its rare disease portfolio with a potential first-in-class oral treatment. Mereo BioPharma will retain commercial rights in the rest of the world and lead the global Phase 3 study and regulatory interactions until completion. This partnership addresses a significant unmet need in a rare genetic respiratory disease affecting an estimated 50,000–80,000 individuals in the United States.

The financial terms of the agreement include a non-refundable option fee paid by Sentynl to Mereo. Upon exercise of the option, Mereo is eligible to receive up to $40 million in upfront and R&D payments until New Drug Application (NDA) filing. Additionally, Mereo will receive double-digit tiered royalties on U.S. net sales of alvelestat. Sentynl also acquires global manufacturing rights for alvelestat for AATD-LD under this arrangement. The companies plan to collaborate during the short option period to refine the Phase 3 study design and advance manufacturing, with the Phase 3 program potentially initiating in early 2027.

Key Agreement Terms

Alvelestat is a novel oral small molecule designed to specifically inhibit neutrophil elastase, a key enzyme involved in inflammation and lung tissue destruction. It has received Orphan Drug Designation for AATD-LD from both the European Commission and the FDA, as well as Fast Track designation from the FDA. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with various respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19, and bronchiolitis obliterans syndrome. Positive efficacy data from two Phase 2 studies backs the preparation for the global Phase 3 study.

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, stated that the partnership marks a pivotal moment for Sentynl's rare disease strategy, adding a highly promising candidate that could address significant unmet needs. Matt Heck, Chief Executive Officer of Sentynl Therapeutics, noted that alvelestat offers an opportunity to improve upon the current standard of care, which often relies on demanding intravenous treatments. Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma, expressed pleasure in partnering with Sentynl, citing its commitment to rare diseases and established commercial infrastructure as ideal for advancing alvelestat.

Zydus Lifesciences Limited reported a 36% year-on-year decline in consolidated net profit to ₹9,398 million for Q1FY27, falling short of estimates due to significant exceptional charges including severance provisions and legal settlements. Despite the bottom-line pressure, the company delivered robust top-line growth with consolidated revenue rising 22% to ₹80,170 million, driven by strong performance in its consumer wellness and pharmaceutical segments. The divergence between revenue growth and profit contraction highlights the impact of one-time costs on operational efficiency during the quarter.

The Board of Directors approved the unaudited financial results on August 11, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by Deloitte Haskins & Sells LLP, the statutory auditors. The trading window for designated persons remains closed until August 14, 2026.

Financial Performance

The company's key consolidated financial metrics for Q1FY27 compared to Q1FY26 are presented below:

Standalone net profit declined 12% to ₹3,396 million from ₹3,847 million in Q1FY26. Standalone revenue increased 11% to ₹28,722 million. The consolidated EBITDA margin contracted by 770 basis points year-on-year to 24.07%, reflecting higher employee benefit expenses and R&D costs. Capex (organic) for the quarter was ₹5,852 million.

Exceptional Items and Operational Costs

The profit decline was largely attributable to non-recurring exceptional items totaling ₹182 million in the consolidated results, compared to nil in the prior year period. Key exceptional charges included:

Additionally, the group recognised a one-time increase in gratuity and leave encashment liability of ₹849 million under the New Labour Codes effective November 21, 2025. Employee benefits expenses rose 38.40% YoY to ₹12,491 million, while R&D expenses increased 32.30% to ₹6,424 million, representing 8% of revenues.

Segmental Highlights

The Pharmaceuticals segment contributed ₹60,900 million to revenue, up 8.60% YoY. Within this, India branded formulations grew 20% YoY to ₹18,158 million, outperforming the market in key therapies like Cardiology and Diabetology. The North America business saw sales decline 2.60% YoY to ₹30,979 million but grew sequentially by 4.90%, driven by volume expansion and new launches, including the first biosimilar NUFYMCO™. International Markets revenue surged 34% YoY to ₹9,735 million.

The Consumer Wellness segment emerged as a key growth driver, with the following performance highlights:

Domestic business grew 5% YoY, while international business delivered 25% YoY growth on a like-to-like basis.

Balance Sheet and Key Metrics

While top-line growth remains strong, particularly in high-margin consumer products, the bottom line was pressured by integration costs and legal provisions associated with recent acquisitions like Assertio Holdings. The substantial receipt from Teva helped offset some of these costs. Tax expenses for Q1FY27 are not directly comparable to prior periods due to the remeasurement of deferred tax assets under Section 115BAA of the Income Tax Act, 1961, which provided a gain of ₹515 million in the preceding quarter.